Skip to main content
CivicGate

HR 1922
Introduced Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.

Ensuring Access to Essential Drugs Act

To amend title XVIII of the Social Security Act to exempt certain drugs from the part D manufacturer discount program under the Medicare program.

Introduced Mar 6, 2025

Latest action (Mar 6, 2025) Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Policy area
Issues
Healthcare

Summary

  • Exempts certain orally administered drugs from Medicare's Part D manufacturer discount program requirements
  • The exemption applies to FDA-approved drugs that have been granted a special exception to be reclassified as non-brand drugs under the Medicaid drug rebate program

AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.

Sponsor (1)

2 cosponsors

Money behind the sponsor

Top reported contributors to Andrew R. Garbarino’s campaign committee (2024 cycle) — who funds the bill’s sponsor, not a claim about this bill. Data from FEC.

  • BLACKSTONE $20,867
  • Employer not reported $20,378
  • HJ KALIKOW CO LLC $16,600
  • NEXTERA ENERGY $15,500
  • MINDSET $11,100

Organizations whose employees gave the most — itemized individual contributions grouped by the donor’s reported employer (FEC Schedule A). Full finance for Andrew R. Garbarino → · Outside spending →

Actions (2)

  1. Mar 6, 2025 Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. · house
  2. Mar 6, 2025 Introduced in House

Full text

IN THE HOUSE OF REPRESENTATIVES

March 6, 2025

Mr. Garbarino (for himself, Mrs. Harshbarger, and Mr. Suozzi) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

A BILL

To amend title XVIII of the Social Security Act to exempt certain drugs from the part D manufacturer discount program under the Medicare program.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the “Ensuring Access to Essential Drugs Act”.

SEC. 2. EXEMPTING CERTAIN DRUGS FROM THE PART D MANUFACTURER DISCOUNT PROGRAM UNDER THE MEDICARE PROGRAM.

Section 1860D-14C(g)(2) of the Social Security Act (42 U.S.C. 1395w-114c(g)(2)) is amended—

(1) in subparagraph (A), by striking “and” at the end;

(2) in subparagraph (B), by striking the period and inserting “; and”; and

(3) by adding at the end the following new subparagraph:

“(C) does not include an orally administered drug—

“(i) for which a new drug application was approved under section 505 of the Federal Food, Drug, and Cosmetic Act; and

“(ii) that has been granted a narrow exception permitting reclassification as a noninnovator multiple source drug under the Medicaid drug rebate program by the Centers for Medicare & Medicaid Services.”. <all>

Text versions (1)

  • Introduced in House · Mar 6, 2025

Only one text version is on file, so there’s no earlier version to compare against yet.

Similar bills (6)

Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.

Comments

Comments

Loading comments…